Related Experiment Video

Updated: May 19, 2026

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
09:31

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals

Published on: April 15, 2017

Human cytomegalovirus inhibitor AL18 also possesses activity against influenza A and B viruses

Giulia Muratore1, Beatrice Mercorelli, Laura Goracci

  • 1Department of Molecular Medicine, University of Padua, Padua, Italy.

Antimicrobial Agents and Chemotherapy
|August 22, 2012
PubMed

Insights

A novel antiviral compound, AL18, initially targeting cytomegalovirus, unexpectedly inhibits influenza A and B virus replication by blocking essential polymerase subunit interactions. This discovery offers a promising new avenue for developing broad-spectrum antiviral therapies.

Area of Science:

  • Virology
  • Drug Discovery
  • Molecular Biology

Background:

  • Human cytomegalovirus (CMV) and influenza viruses are significant human pathogens.
  • Antiviral drug development often involves repurposing existing compounds or identifying novel mechanisms of action.

Purpose of the Study:

  • To investigate the unexpected antiviral activity of AL18, a CMV DNA polymerase inhibitor, against influenza viruses.
  • To elucidate the molecular mechanism by which AL18 affects influenza virus replication.

Main Methods:

  • Biochemical assays to assess polymerase activity.
  • Viral replication assays in cell culture.
  • Molecular modeling to predict drug-target interactions.

Main Results:

  • AL18 was found to inhibit the interaction between PB1 and PA polymerase subunits of influenza A virus.
  • AL18 demonstrated potent inhibition of influenza A virus polymerase activity.
  • AL18 effectively suppressed the replication of both influenza A and B viruses.

Conclusions:

  • AL18 exhibits dual activity, inhibiting both CMV and influenza virus replication.
  • The compound acts by disrupting the influenza virus polymerase complex.
  • AL18 represents a promising lead compound for developing new antiviral agents against influenza and potentially other viruses.

More Related Videos

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses09:07

Using Zebrafish Models of Human Influenza A Virus Infections to Screen Antiviral Drugs and Characterize Host Immune Cell Responses

Published on: January 20, 2017

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Leaky Scanning02:28

Leaky Scanning

During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA.  Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...